SEC v. Joseph Geromini, No. LR-25120, District of New Jersey (June 23, 2021) — Press Release
raw: Joseph Geromini
Joseph Geromini, No. LR-25120 (D.N.J. June 23, 2021)
Joseph Geromini, former COO of a Philadelphia medical‑devices company, was charged by the SEC with defrauding investors by misappropriating over $200,000 from two 2018 securities offerings for personal expenses.
The SEC alleges Geromini used false offering documents and misleading financial models to persuade investors that the proceeds would be used for company operations. In reality, he diverted more than $200,000 to fund a car purchase, vacations, and cosmetic surgery. He is charged with violating the antifraud provisions of the Securities Act of 1933.
Joseph Geromini, who served as chief operating officer of a Philadelphia‑based medical‑devices firm, is accused of a securities fraud scheme involving two 2018 offerings. The SEC says he presented investors with falsified offering memoranda and optimistic cash‑burn projections, claiming the capital would support product development and working capital. Instead, Geromini siphoned over $200,000 of the raised funds for personal use, including a luxury automobile, vacation trips, and cosmetic surgery. By misrepresenting the company’s financial health, he inflated the perceived cash‑burn rate to mask his theft. The agency has charged him with violating the antifraud provisions of the Securities Act of 1933. If convicted, Geromini could face civil penalties, disgorgement, and an injunction against future securities violations.
Exhibits & Attached Documents (1)
Extracted insights
- $200K $200,000 $100K–$1M
- person chief operating officer
- person defrauding investors
- person joseph geromini
- person misappropriating proceeds
- agency Securities and Exchange Commission
- agency the sec's complaint
- agency the securities and exchange commission
- court u.s. district court for the district of new jersey
- The Securities and Exchange Commission charged Joseph Geromini
- The SEC's complaint alleges Joseph Geromini
- Joseph Geromini defrauding investors
- Joseph Geromini misappropriating proceeds from two securities offerings
- SEC charged Joseph Geromini with Defrauding Investors
- The Securities and Exchange Commission charged Joseph Geromini
- Joseph Geromini defrauded investors through two securities offerings while serving as Chief Operating Officer of a medical devices company
- Securities and Exchange Commission charged Joseph Geromini with defrauding investors and misappropriating proceeds from two securities offerings
- The Securities and Exchange Commission charged Joseph Geromini
- Joseph Geromini defrauding investors
- Joseph Geromini misappropriating proceeds from two securities offerings
- Joseph Geromini defrauded investors through two securities offerings while serving as Chief Operating Officer of a medical devices company
- Securities and Exchange Commission charged Joseph Geromini with defrauding investors and misappropriating proceeds from two securities offerings
- Securities and Exchange Commission charged Joseph Geromini
- Joseph Geromini charged with defrauding investors
- Joseph Geromini charged with misappropriating proceeds
- Joseph Geromini was Chief Operating Officer
- Joseph Geromini filed Civil Action No. 1:21-civ-12880
- Securities and Exchange Commission filed complaint
- Joseph Geromini defrauded investors through two securities offerings while serving as Chief Operating Officer of a medical devices company
- Securities and Exchange Commission charged Joseph Geromini with defrauding investors and misappropriating proceeds from two securities offerings
- Joseph Geromini defrauded investors through two securities offerings while serving as Chief Operating Officer of a medical devices company
- Securities and Exchange Commission charged Joseph Geromini with defrauding investors and misappropriating proceeds from two securities offerings
- Joseph Geromini defrauded investors through two securities offerings while serving as Chief Operating Officer of a medical devices company
- Securities and Exchange Commission charged Joseph Geromini with defrauding investors and misappropriating proceeds from two securities offerings
- Joseph Geromini defrauded investors through two securities offerings while serving as Chief Operating Officer of a medical devices company
- Securities and Exchange Commission charged Joseph Geromini with defrauding investors and misappropriating proceeds from two securities offerings
- Joseph Geromini defrauded investors through two securities offerings while serving as Chief Operating Officer of a medical devices company
- Securities and Exchange Commission charged Joseph Geromini with defrauding investors and misappropriating proceeds from two securities offerings
- SEC charged Joseph Geromini
- Joseph Geromini charged with defrauding investors
- Joseph Geromini charged with misappropriating proceeds
- Joseph Geromini was Chief Operating Officer
- Joseph Geromini filed Civil Action No. 1:21-civ-12880
- Securities and Exchange Commission filed complaint
- Joseph Geromini based in Philadelphia, Penn
- The Securities and Exchange Commission charged Joseph Geromini
- Joseph Geromini defrauded investors
- Joseph Geromini misappropriated proceeds from two securities offerings
- The SEC's complaint alleges Joseph Geromini was the Chief Operating Officer of an early-stage medical devices company based in Philadelphia
- The SEC's complaint filed U.S. District Court for the District of New Jersey
- Civil Action No. 1:21-civ-12880 filed June 23, 2021
- Litigation Release No. 25120 dated June 23, 2021
- Securities and Exchange Commission charged Joseph Geromini
- Joseph Geromini charged with defrauding investors
- Joseph Geromini charged with misappropriating proceeds
- Joseph Geromini was Chief Operating Officer
- Joseph Geromini filed Civil Action No. 1:21-civ-12880
- Securities and Exchange Commission filed complaint
- SEC charged Joseph Geromini with defrauding investors
- SEC charged Joseph Geromini with misappropriating proceeds from two securities offerings
- SEC filed complaint in the U.S. District Court for the District of New Jersey
- Joseph Geromini was Chief Operating Officer of an early-stage medical devices company based in Philadelphia
SEC Charges Former Company Executive with Defrauding Investors Litigation Release No. 25120 / June 23, 2021 Securities and Exchange Commission v. Joseph Geromini, Civil Action No. 1:21-civ-12880 (D.N.J. filed June 23, 2021) The Securities and Exchange Commission today charged a New Jersey resident with defrauding investors and misappropriating proceeds from two securities offerings. The SEC's complaint, filed in the U.S. District Court for the District of New Jersey, alleges that Joseph Geromini, while he was the Chief Operating Officer of an early-stage medical devices company based in Philadelphia, Pennsylvania, lied to investors and stole over $200,000 raised during two 2018 securities offerings. According to the complaint, Geromini disseminated offering documents and financial models to investors that he knew were false and misleading because they did not account for his ongoing theft of investor proceeds. In addition, Geromini allegedly made materially false and misleading statements and omissions during communications with investors about the company's cash burn rate and use of proceeds. For example, the complaint alleges that Geromini falsely told investors that "every penny" of their money would be used in a meaningful, productive manner, when, in reality, he used funds raised during the offerings for personal expenses, including a car, an acquaintance's cosmetic surgery, a vacation, and other entertainment. The SEC's complaint charges Geromini with violating the antifraud provisions of Section 17(a) of the Securities Act of 1933, as well as Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. Without admitting or denying the allegations, Geromini has agreed to settle the charges against him. The settlement, which is subject to court approval, would permanently enjoin Geromini from violating the charged provisions of the federal securities laws and prohibit him from acting as an officer or director of a publicly-traded company. The settlement further provides that the court will decide the amounts of disgorgement, prejudgment interest, and civil penalties at a later date. The SEC's investigation was conducted by Brian R. Higgins and Oreste P. McClung of the Philadelphia Regional Office and supervised by Brendan P. McGlynn and Scott A. Thompson. The litigation will be led by Michael S. Macko and supervised by Jennifer Chun Barry. SEC Complaint
SEC Charges Former Company Executive with Defrauding Investors Litigation Release No. 25120 / June 23, 2021 Securities and Exchange Commission v. Joseph Geromini, Civil Action No. 1:21-civ-12880 (D.N.J. filed June 23, 2021) The Securities and Exchange Commission today charged a New Jersey resident with defrauding investors and misappropriating proceeds from two securities offerings. The SEC's complaint, filed in the U.S. District Court for the District of New Jersey, alleges that Joseph Geromini, while he was the Chief Operating Officer of an early-stage medical devices company based in Philadelphia, Pennsylvania, lied to investors and stole over $200,000 raised during two 2018 securities offerings. According to the complaint, Geromini disseminated offering documents and financial models to investors that he knew were false and misleading because they did not account for his ongoing theft of investor proceeds. In addition, Geromini allegedly made materially false and misleading statements and omissions during communications with investors about the company's cash burn rate and use of proceeds. For example, the complaint alleges that Geromini falsely told investors that "every penny" of their money would be used in a meaningful, productive manner, when, in reality, he used funds raised during the offerings for personal expenses, including a car, an acquaintance's cosmetic surgery, a vacation, and other entertainment. The SEC's complaint charges Geromini with violating the antifraud provisions of Section 17(a) of the Securities Act of 1933, as well as Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. Without admitting or denying the allegations, Geromini has agreed to settle the charges against him. The settlement, which is subject to court approval, would permanently enjoin Geromini from violating the charged provisions of the federal securities laws and prohibit him from acting as an officer or director of a publicly-traded company. The settlement further provides that the court will decide the amounts of disgorgement, prejudgment interest, and civil penalties at a later date. The SEC's investigation was conducted by Brian R. Higgins and Oreste P. McClung of the Philadelphia Regional Office and supervised by Brendan P. McGlynn and Scott A. Thompson. The litigation will be led by Michael S. Macko and supervised by Jennifer Chun Barry. SEC Complaint